AI summary · may contain errors
A knobless fowl adenovirus type 1 fiber–fused soluble TRAIL variant, mut-FA1TLST, reduced liver tropism and enhanced antitumor activity of an oncolytic adenovirus in vitro and in vivo.
American Association for Cancer Research · Oncology · ISSN 1535-7163, 1538-8514
Rebuilt
Newest first · last 60 days
AI summary · may contain errors
A knobless fowl adenovirus type 1 fiber–fused soluble TRAIL variant, mut-FA1TLST, reduced liver tropism and enhanced antitumor activity of an oncolytic adenovirus in vitro and in vivo.
AI summary · may contain errors
In 29 patient-derived and established tumor spheroid models, pan-RAS(ON) daraxonrasib (RMC-6236) suppressed growth across diverse RAS alterations and wild-type RAS.
AI summary · may contain errors
Ifabotuzumab-PBD ADC is the most efficacious EphA3-targeted antibody-drug conjugate, showing highest in-vitro potency and the strongest tumour growth reduction and survival benefit in mice.
AI summary · may contain errors
Targeting H3K9me3 with F5446 suppresses colon tumor liver metastasis in a syngeneic mouse model by shifting exhausted Tex cells toward IFNγhighPD-1low and IFNγhigh Tex-int states.
AI summary · may contain errors
A quantitative immunofluorescence assay measured HER3, EGFR, and TROP2 protein across 329 HNSCC patients, with 100%, 97.5%, and 98.4% of cases above assay LOD.
AI summary · may contain errors
GenSci143, a B7-H3 × PSMA-directed bispecific antibody-drug conjugate, produced profound tumor regression in prostate cancer xenograft models and showed superior antitumor activity versus competitor ADCs.
AI summary · may contain errors
β-catenin, encoded by CTNNB1, is part of a major WNT oncogenic axis present in approximately 10% of human cancers, making it a prime precision oncology target.
AI summary · may contain errors
LZK inhibition suppresses AKT activation and limits tumor growth in MAP3K13-amplified esophageal squamous cell carcinoma xenografts, with AKT phosphorylation at S473/T450 reduced.
AI summary · may contain errors
High HERV-K expression in diffuse large B-cell lymphoma is linked to an interferon/viral-mimicry program, and Env protein appears on the surface of a subset of cell lines.
AI summary · may contain errors
ADCE-T02, a tissue factor–targeting ADC with an average drug-to-antibody ratio of 4.5, shows strong preclinical efficacy and is well tolerated in nonhuman primates.
AI summary · may contain errors
In 12 lung cancer patients with resistance after EGFR/MET inhibition, 5 (42%) acquired oncogenic fusions, including BRAF, ALK, and RET, highlighting a targetable resistance route.
AI summary · may contain errors
QW-5-70, a colchicine binding site inhibitor, maintains low-nanomolar antitumor activity in vincristine-resistant BE2C/VCR and paclitaxel-resistant PC-3/TxR models despite P-gp overexpression.
AI summary · may contain errors
High GITR RNA expression is linked to better restricted mean survival time in 489 patients with advanced/metastatic cancers, including 272 not treated with immunotherapy.
AI summary · may contain errors
89Zr-CB307 PET shows selective accumulation in PSMA-positive metastatic castration-resistant prostate cancer lesions, with liver uptake (SUVmean 13.06 ± 2.68 at day 7) and no spleen or marrow uptake.
AI summary · may contain errors
BLU-451 is a CNS-active, selective EGFR tyrosine kinase inhibitor that suppresses exon 20 insertion phosphorylated EGFR in tumor tissue while sparing skin and intestinal tissues.
AI summary · may contain errors
CDK12-knockout prostate cancer cells show an ATM-like DSB response phenotype and are sensitized to ATR inhibition, with combined PARP plus ATR suppressing growth in CDK12-defective patient-derived xenografts.
AI summary · may contain errors
PTC596 controls H22 and Hepa1-6 hepatocellular carcinoma tumor growth in Balb/c and C57BL/6 mice and, with anti-PD-1, prolongs survival.
Journals this month
Topics moving, week to 17 Nov 2026
By field